Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Dec 21;32(12):690–694. doi: 10.1002/clc.20611

N‐terminal Prohormone Brain Natriuretic Peptide‐proBNP Levels in Ventricular Arrhythmias in Children

Bogusław Mazurek 1,✉, Lesław Szydłowski 1, Grażyna Giec‐Fuglewicz 1, Grażyna Markiewicz‐Łoskot 2
PMCID: PMC6653564  PMID: 20027660

Abstract

Background

Ventricular arrhythmias are the most common consequences of structural and functional heart diseases, but cases with no evident pathology are also observed. A parameter indicating asymptomatic circulatory failure could support decisions related to possible treatment of ventricular arrhythmias.

Hypothesis

The study objective was the evaluation of N‐terminal prohormone brain natriuretic peptide (NT‐proBNP) levels in children with ventricular arrhythmias and an attempt to determine if this parameter may be used for diagnosis and prognosis of ventricular arrhythmias.

Material and methods

The study population was comprised of 36 children age 5 to 17.5 years old with idiopathic ventricular arrhythmias (Group B) graded mild or potentially malignant; 29 patients with mild ventricular arrhythmias were included into Group B1; and 7 patients with potentially malignant cases into Group B2. In all the patients, NT‐proBNP assays were performed.

Results

The NT‐proBNP levels in Groups B, B1, B2 and the control group (Group K) were as follows: 41.5 ± 15.1 pg/mL, 35.5 ± 18.5 pg/mL, 66.3 ± 24.9 pg/mL and 31.5 ± 15.1 pg/mL, respectively. Between the groups with and without arrhythmias (Group B vs Group K), no statistically significant differences in NT‐proBNP levels were found. However, markedly higher NT‐proBNP levels were shown in the children with potentially malignant arrhythmias (Group B2) compared to the patients with mild arrhythmias (B1) and the control group (Group K).

Conclusions

The level of NT‐proBNP increases with the severity of ventricular arrhythmia. NT‐proBNP assays can be helpful for diagnosing and grading the severity of ventricular arrhythmias. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (102.2 KB).

References

  • 1. Bigger J.T. Jr. Definition of benign versus malignant ventricular arrhythmias: targets for treatment. Am. J. Cardiol 1983; 52(supl.C): 47C–54C. [DOI] [PubMed] [Google Scholar]
  • 2. Alexander M, Berul C. Ventricular arrhythmias: When to worry. Pediatr Cardiol 2000; 21: 532–541. [DOI] [PubMed] [Google Scholar]
  • 3. Ogawa K, Oida A, Sugimura H, et al. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients—comparison of electrocardiography, chest radiography and echocardiography. Circ J 2002; 66: 122–126. [DOI] [PubMed] [Google Scholar]
  • 4. Hammerer‐Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab 2001; 47: 265–277. [PubMed] [Google Scholar]
  • 5. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24(3): 341–356. [DOI] [PubMed] [Google Scholar]
  • 6. Taniguchi R, Sato Y, Yamada T, et al. Combined measurements of cardiac troponin T and N‐terminal pro‐brain natriuretic peptide in patients with heart failure. Circ J 2004; 68: 1160–1164. [DOI] [PubMed] [Google Scholar]
  • 7. Maisel A. B‐type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail 2001; 7(2): 83–192. [DOI] [PubMed] [Google Scholar]
  • 8. Berger R, Huelsman M, Strecker K, et al. B‐type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2397. [DOI] [PubMed] [Google Scholar]
  • 9. Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on base of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003; 108: 2368–2376. [DOI] [PubMed] [Google Scholar]
  • 10. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the biomedical NT‐pro BNP enzyme immunoassay and the Roche NT‐proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003; 49(6): 976–979. [DOI] [PubMed] [Google Scholar]
  • 11. Mir T, Marohn S, Läer S, et al. Plasma concentrations of N‐terminal pro‐brain natriuretic peptide in control children from neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002; 110: 76–82. [DOI] [PubMed] [Google Scholar]
  • 12. De Lemons J, Mcguire D, Drazner M. B‐type natriuretic peptide in cardiovascular disease. Lancet 2003; 361(9370): 4997–5004. [DOI] [PubMed] [Google Scholar]
  • 13. McDonagh T, Robb S, Murdoch D, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351: 9–13. [DOI] [PubMed] [Google Scholar]
  • 14. Ramachandran S, Vasan M, Emelia J, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. The Framingham Heart Study. JAMA 2002; 288: 1252–1259. [DOI] [PubMed] [Google Scholar]
  • 15. Hammerer‐Lercher A, Neubauer E, Muller S, et al. Head‐to‐head comparison of the N‐terminal pro‐brain natriuretic peptide, brain natriuretic peptide and N‐terminal pro‐atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001; 310: 193–197. [DOI] [PubMed] [Google Scholar]
  • 16. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89: 875–878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Nir A, Bar‐Oz B, Perles Z, et al. N‐terminal pro‐B‐type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004; 93: 603–607. [DOI] [PubMed] [Google Scholar]
  • 18. Kawamura T, Wago M, Kawaguchi H, et al. Plasma brain natriuretic concentrations in patients with Kawasaki disease. Pediatr Int 2000; 42: 241–248. [DOI] [PubMed] [Google Scholar]
  • 19. Westerlind A, Wahlander H, Lindstedt G, et al. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004; 93: 340–345. [DOI] [PubMed] [Google Scholar]
  • 20. Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003; 57(4): 191–197. [DOI] [PubMed] [Google Scholar]
  • 21. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatric International 2003; 45: 249–254. [DOI] [PubMed] [Google Scholar]
  • 22. Koch A, Zink St, Singer H. B‐type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006; 27(7): 861–866. [DOI] [PubMed] [Google Scholar]
  • 23. Sutovsky I, Katoh T, Ohno T, et al. Relationship between brain natriuretic peptide, myocardial wall stress and ventricular arrhythmia severity. Jpn Heart J 2004; 45: 771–777. [DOI] [PubMed] [Google Scholar]
  • 24. Tada H, Ito S, Dhinbo G, et al. Significance and utility of plasma natriuretic peptide concentrations in patients with idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol 2006; 29(12): 1395–1403. [DOI] [PubMed] [Google Scholar]
  • 25. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000; 102: 3074–3079. [DOI] [PubMed] [Google Scholar]
  • 26. Liang F, Gardner D. Mechanical strain activates BNP gene transcription through a p38/NF‐kB‐dependent mechanism. J Clin Invest 1999; 104: 1603–1612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Stoddard M, Pearson A, Kern M, et al. The effect of premature ventricular contraction on left ventricular relaxation, chamber stiffness and filling in humans. Am Heart J 1989; 118(4): 725–733. [DOI] [PubMed] [Google Scholar]
  • 28. Facchini M, Malfatto G, Ciambelotti F, et al. Increased left ventricular dimensions in patients with frequent nonsustained ventricular arrhythmias and no evidence of underlying disease. J Cardiovasc Electrophysiol 1999; 10: 1433–1438. [DOI] [PubMed] [Google Scholar]
  • 29. Sun Y, Blom N, Yonghui Y, Peiran Ma. The influence of premature ventricular contractions on left ventricular function in asymptomatic children without structural heart disease: an echocardiographic evaluation. Int J Card Imaging 2003; 19(4): 295–299. [DOI] [PubMed] [Google Scholar]
  • 30. Troughton R, Frampton C, Yandle T, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N‐BNP) concentrations. Lancet 2000; 355(9210): 1126–1130. [DOI] [PubMed] [Google Scholar]
  • 31. Shiga T, Hosaka F, Wakaumi M. Amiodarone decreases plasma brain natriuretic peptide level in patients with heart failure and ventricular tachyarrhythmia. Cardiovasc Drugs Ther 2003; 17: 325–331. [DOI] [PubMed] [Google Scholar]
  • 32. Molinari G, Sardanelli F, Zandrino F, et al. Adipose replacement and wall motion abnormalities in right ventricle arrhythmias: evaluation by MR imaging. Retrospective evaluation on 124 patients. Int J Card Imaging 2000; 16(2): 105–115. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES